Cover Image
市場調查報告書

Bukwang Pharm.Co., Ltd.的產品平台分析

Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 320913
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Bukwang Pharm.Co., Ltd.的產品平台分析 Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 29 Pages
簡介

Bukwang Pharm.Co., Ltd.是總公司位於韓國的生物科技企業,正在研發新醫藥產品。b型肝炎、糖尿病性神經病變、肝損傷、季節性過敏、支氣管氣喘等疾病治療藥的開發。

本報告提供Bukwang Pharm.Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Bukwang Pharm.Co., Ltd.的基本資料

  • Bukwang Pharm.Co., Ltd.概要
  • 主要資訊
  • 企業資料

Bukwang Pharm.Co., Ltd.:R&D概要

  • 主要的治療範圍

Bukwang Pharm.Co., Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Bukwang Pharm.Co., Ltd.:開發中產品概況

  • 後期階段產品開發中產品
    • 申請不受理/申請撤回產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 開發階段不明的產品/聯合治療模式

Bukwang Pharm.Co., Ltd.:藥物簡介

  • clevudine
  • YN-968D1
  • MLR-1023

Bukwang Pharm.Co., Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Bukwang Pharm.Co., Ltd.:最新的開發平台資訊

Bukwang Pharm.Co., Ltd.:開發暫停中的計劃

Bukwang Pharm.Co., Ltd.:開發中止的開發中產品

Bukwang Pharm.Co., Ltd.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06606CDB

Summary

Global Markets Direct's, 'Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Bukwang Pharm.Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bukwang Pharm.Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Bukwang Pharm.Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Bukwang Pharm.Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Bukwang Pharm.Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Bukwang Pharm.Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Bukwang Pharm.Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Bukwang Pharm.Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Bukwang Pharm.Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bukwang Pharm.Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Bukwang Pharm.Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bukwang Pharm.Co., Ltd. Snapshot
    • Bukwang Pharm.Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Bukwang Pharm.Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Bukwang Pharm.Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Bukwang Pharm.Co., Ltd. - Pipeline Products Glance
    • Bukwang Pharm.Co., Ltd. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
    • Bukwang Pharm.Co., Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Bukwang Pharm.Co., Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Bukwang Pharm.Co., Ltd. - Drug Profiles
    • clevudine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YN-968D1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLR-1023
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bukwang Pharm.Co., Ltd. - Pipeline Analysis
    • Bukwang Pharm.Co., Ltd. - Pipeline Products by Target
    • Bukwang Pharm.Co., Ltd. - Pipeline Products by Route of Administration
    • Bukwang Pharm.Co., Ltd. - Pipeline Products by Molecule Type
    • Bukwang Pharm.Co., Ltd. - Pipeline Products by Mechanism of Action
  • Bukwang Pharm.Co., Ltd. - Recent Pipeline Updates
  • Bukwang Pharm.Co., Ltd. - Dormant Projects
  • Bukwang Pharm.Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • clevudine
  • Bukwang Pharm.Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bukwang Pharm.Co., Ltd., Key Information
  • Bukwang Pharm.Co., Ltd., Key Facts
  • Bukwang Pharm.Co., Ltd. - Pipeline by Indication, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Stage of Development, 2014
  • Bukwang Pharm.Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Bukwang Pharm.Co., Ltd. - Partnered Products in Pipeline, 2014
  • Bukwang Pharm.Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • Bukwang Pharm.Co., Ltd. - Filing rejected/Withdrawn, 2014
  • Bukwang Pharm.Co., Ltd. - Phase I, 2014
  • Bukwang Pharm.Co., Ltd. - Unknown, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Target, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Route of Administration, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Molecule Type, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Bukwang Pharm.Co., Ltd. - Recent Pipeline Updates, 2014
  • Bukwang Pharm.Co., Ltd. - Dormant Developmental Projects,2014
  • Bukwang Pharm.Co., Ltd. - Discontinued Pipeline Products, 2014

List of Figures

  • Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Stage of Development, 2014
  • Bukwang Pharm.Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Bukwang Pharm.Co., Ltd. - Partnered Products in Pipeline, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Target, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Bukwang Pharm.Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top